| 000 | 01854 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250514225551.0 | ||
| 264 | 0 | _c20050630 | |
| 008 | 200506s 0 0 eng d | ||
| 022 | _a0586-7614 | ||
| 024 | 7 |
_a10.1093/schbul/sbi020 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBuchanan, Robert W | |
| 245 | 0 | 0 |
_aA summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. _h[electronic resource] |
| 260 |
_bSchizophrenia bulletin _cJan 2005 |
||
| 300 |
_a5-19 p. _bdigital |
||
| 500 | _aPublication Type: Congress; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 | _aAntipsychotic Agents |
| 650 | 0 | 4 | _aBrief Psychiatric Rating Scale |
| 650 | 0 | 4 |
_aClinical Trials as Topic _xstandards |
| 650 | 0 | 4 |
_aCognition Disorders _xdiagnosis |
| 650 | 0 | 4 | _aCombined Modality Therapy |
| 650 | 0 | 4 | _aGuidelines as Topic |
| 650 | 0 | 4 | _aHealth Promotion |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aMental Health Services _xstandards |
| 650 | 0 | 4 | _aNational Institute of Mental Health (U.S.) |
| 650 | 0 | 4 | _aPolypharmacy |
| 650 | 0 | 4 | _aPsychotherapy |
| 650 | 0 | 4 |
_aSchizophrenia _xcomplications |
| 650 | 0 | 4 | _aSeverity of Illness Index |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aUnited States |
| 650 | 0 | 4 | _aUnited States Food and Drug Administration |
| 700 | 1 | _aDavis, Miriam | |
| 700 | 1 | _aGoff, Donald | |
| 700 | 1 | _aGreen, Michael F | |
| 700 | 1 | _aKeefe, Richard S E | |
| 700 | 1 | _aLeon, Andrew C | |
| 700 | 1 | _aNuechterlein, Keith H | |
| 700 | 1 | _aLaughren, Thomas | |
| 700 | 1 | _aLevin, Robert | |
| 700 | 1 | _aStover, Ellen | |
| 700 | 1 | _aFenton, Wayne | |
| 700 | 1 | _aMarder, Steve R | |
| 773 | 0 |
_tSchizophrenia bulletin _gvol. 31 _gno. 1 _gp. 5-19 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1093/schbul/sbi020 _zAvailable from publisher's website |
| 999 |
_c15551238 _d15551238 |
||